Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020.
2020
Circulating vaccine derived polio virus type 1 outbreak
Saadah governorate
Yemen
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
29 Apr 2022
29 Apr 2022
Historique:
received:
04
08
2021
accepted:
18
04
2022
entrez:
29
4
2022
pubmed:
30
4
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Yemen has faced one of the worst humanitarian crises in the world since the start of the war in 2015. In 2020; 30 Vaccine Derived Polio Virus type 1 (VDPV1) isolates were detected in Saadah governorate. The aims are to characterize the outbreak and address the gaps predisposing the emergence and circulation of VDPV1 in Saadah governorate, Yemen. A retrospective descriptive study of confirmed cases of VDPV1 between January and December 2020 was performed. Surveillance staff collected data from patient cases, contacts, as well as stool specimens that shipped to WHO accredited polio labs. Data of population immunity was also reviewed. The difference in days between the date of sample collection, shipment, and receiving lab result was used to calculate the average of delayed days for lab confirmation. From January to December 2020, a total of 114 cases of acute flaccid paralysis (AFP) were reported from 87% (13/15) districts, and cVDPV1 was confirmed among 26% (30) AFP cases. 75% (21) were < 5 years, 73% (20) had zero doses of Oral Polio Vaccine (OPV). The first confirmed case (3%) was from Saadah city, with paralysis onset at the end of January 2020 followed by 5 cases (17%) in March from another four districts, 8 cases (27%) in April, and 13 (43%) up to December 2020 were from the same five districts in addition to 3 (10%) form three new districts. The lab confirmation was received after an average of 126 days (71-196) from sample collection. The isolates differ from the Sabin 1 type by 17- 30 VP1 nucleotides (nt) and were linked to VDPV1 with 13 (nt) divergence that isolated in July 2020 from stool specimens collected before one year from contacts of an inadequate AFP case reported from Sahar district. The new emerging VDPV1 was retrospectively confirmed after one year of sample collection from Sahar district. Delayed lab confirmation, as well as the response and low immunization profile of children against polio, were the main predisposing factors for cVDPV1 outbreak. This outbreak highlights the need to maintain regular biweekly shipments to referral polio labs in the short-term, and the exploration of other options in the longer-term to enable the Yemen National Lab to fully process national samples itself.
Sections du résumé
BACKGROUND
BACKGROUND
Yemen has faced one of the worst humanitarian crises in the world since the start of the war in 2015. In 2020; 30 Vaccine Derived Polio Virus type 1 (VDPV1) isolates were detected in Saadah governorate. The aims are to characterize the outbreak and address the gaps predisposing the emergence and circulation of VDPV1 in Saadah governorate, Yemen.
METHOD
METHODS
A retrospective descriptive study of confirmed cases of VDPV1 between January and December 2020 was performed. Surveillance staff collected data from patient cases, contacts, as well as stool specimens that shipped to WHO accredited polio labs. Data of population immunity was also reviewed. The difference in days between the date of sample collection, shipment, and receiving lab result was used to calculate the average of delayed days for lab confirmation.
RESULTS
RESULTS
From January to December 2020, a total of 114 cases of acute flaccid paralysis (AFP) were reported from 87% (13/15) districts, and cVDPV1 was confirmed among 26% (30) AFP cases. 75% (21) were < 5 years, 73% (20) had zero doses of Oral Polio Vaccine (OPV). The first confirmed case (3%) was from Saadah city, with paralysis onset at the end of January 2020 followed by 5 cases (17%) in March from another four districts, 8 cases (27%) in April, and 13 (43%) up to December 2020 were from the same five districts in addition to 3 (10%) form three new districts. The lab confirmation was received after an average of 126 days (71-196) from sample collection. The isolates differ from the Sabin 1 type by 17- 30 VP1 nucleotides (nt) and were linked to VDPV1 with 13 (nt) divergence that isolated in July 2020 from stool specimens collected before one year from contacts of an inadequate AFP case reported from Sahar district.
CONCLUSION
CONCLUSIONS
The new emerging VDPV1 was retrospectively confirmed after one year of sample collection from Sahar district. Delayed lab confirmation, as well as the response and low immunization profile of children against polio, were the main predisposing factors for cVDPV1 outbreak. This outbreak highlights the need to maintain regular biweekly shipments to referral polio labs in the short-term, and the exploration of other options in the longer-term to enable the Yemen National Lab to fully process national samples itself.
Identifiants
pubmed: 35488227
doi: 10.1186/s12879-022-07397-0
pii: 10.1186/s12879-022-07397-0
pmc: PMC9052627
doi:
Substances chimiques
Poliovirus Vaccine, Oral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
414Informations de copyright
© 2022. The Author(s).
Références
MMWR Morb Mortal Wkly Rep. 2016 Aug 05;65(30):763-9
pubmed: 27491079
MMWR Morb Mortal Wkly Rep. 2017 Nov 03;66(43):1185-1191
pubmed: 29095803
Risk Anal. 2013 Apr;33(4):680-702
pubmed: 23470192
JMIR Public Health Surveill. 2019 Dec 6;5(4):e14413
pubmed: 31808749
BMC Infect Dis. 2015 Feb 18;15:66
pubmed: 25886823
J Clin Microbiol. 2010 Sep;48(9):3274-80
pubmed: 20631095
Microbiol Spectr. 2021 Dec 22;9(3):e0066821
pubmed: 34756088
MMWR Morb Mortal Wkly Rep. 2019 Feb 08;68(5):119-120
pubmed: 30730867
Global Health. 2020 Jul 16;16(1):63
pubmed: 32677974
PLoS One. 2014 Dec 11;9(12):e113880
pubmed: 25503964
MMWR Morb Mortal Wkly Rep. 2020 Apr 24;69(16):489-495
pubmed: 32324719
J Infect Dis. 2017 Jul 1;216(suppl_1):S299-S307
pubmed: 28838192
Science. 2002 Apr 12;296(5566):356-9
pubmed: 11896235
MMWR Morb Mortal Wkly Rep. 2018 Mar 16;67(10):300-305
pubmed: 29543791
Risk Anal. 2013 Apr;33(4):544-605
pubmed: 22804479
MMWR Morb Mortal Wkly Rep. 2016 Feb 12;65(5):128-9
pubmed: 26866942
MMWR Morb Mortal Wkly Rep. 2019 Nov 15;68(45):1024-1028
pubmed: 31725706
Annu Rev Microbiol. 2005;59:587-635
pubmed: 16153180
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32611795
Bull World Health Organ. 2004 Jan;82(1):16-23
pubmed: 15106296
J Gen Virol. 1981 Oct;56(Pt 2):337-47
pubmed: 6273502
Risk Anal. 2006 Dec;26(6):1471-505
pubmed: 17184393
JMIR Public Health Surveill. 2019 Oct 23;5(4):e14461
pubmed: 31647465
Vaccine. 2017 Aug 24;35(36):4769-4776
pubmed: 28528761
Biologicals. 2006 Jun;34(2):103-8
pubmed: 16650771
JMIR Public Health Surveill. 2021 May 19;7(5):e27638
pubmed: 34009132
J Infect Dis. 2006 Sep 1;194(5):545-51
pubmed: 16897650
PLoS One. 2014 Feb 18;9(2):e88442
pubmed: 24558390